Learn More
Supporting Drug Discovery
De Novo has now launched an in silico drug discovery platform for standalone use. Our objective is to make in silico drug design available to medicinal chemists and computational scientists throughout the pharmaceutical industry and academia.

Contact us if you are interested in any aspect of drug discovery from focused chemical libraries to scaffold-hopping.

Print this page

Recent News
De Novo Pharmaceuticals Ltd. Announces New Therapeutic Focus In the Area Of Metabolic Diseases And Appoints New Scientific Advisory Board.
De Novo Pharmaceuticals Ltd Announces Drug Discovery Collaboration Agreement with Genzyme
De Novo launches Reflex, a major upgrade to its in silico drug design platform
De Novo Agrees Med Chem Synthesis Deal
De Novo Launches Academic Access Programme
De Novo Takes SkelGen to Japan
De Novo Launches ‘Stand-Alone; SkelGen
De Novo signs first academic licence with the University of Hertfordshire
De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen
De Novo Pharmaceuticals Ltd. Announces New Partnering Opportunity in Diabetes